GDF -15 and Severity Scores in Sickle Cell Disease Patients Attending Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria

Main Article Content

Chide Okocha
Patrick Manafa
Joy Anowi
Vera Manafa
Chilota Efobi


Aim: Granulocyte differentiation factor 15 (GDF15) is a growth factor and biomarker for many disorders where Ischaemia Reperfusion Injury (IRI) is pathophysiologically relevant. Hence the need to evaluate GDF-15 as a biomarker in Sickle Cell Disease (SCD).

Study Design: This is a cross sectional study.

Place and Duration of Study: Department of Haematology, Nnamdi University Teaching Hospital, Nnewi, Anambra state, Nigeria, between January and December 2018.

Methods: Ninety subjects were randomly recruited with haemoglobin (Hb) phenotypes SS (test), AS and AA (controls); numbering 30, 28 and 32 respectively. Disease severity was determined by calculating an objective score. 5 mls of blood was collected and used to determine Full Blood Count (FBC), haemoglobin Phenotype and GDF-15 levels (by Enzyme Linked Immunosorbent assay).  Data collected was analysed using Statistical Package for Social Sciences software version 20 (SPSS Inc., IL, Chicago, USA). P< 0.05 was considered as significant.

Results: GDF-15 level was found to be significantly different in the different HB phenotypes p= 0.005 and correlated negatively with sickle cell disease severity (r= -0.307, p= 0.098). The difference between median GDF-15 levels of HBSS subjects with mild and moderate disease was statistically significant at p= 0.01.

Conclusion: We hypothesize that GDF-15 may be a potential therapeutic target for intervention against ischaemia/reperfusion induced micro- vascular injury.  Natural GDF-15 mimetics may be useful in taking advantage of this potential therapeutic target.

GDF- 15, sickle cell disease, ischaemia reperfusion injury, GDF-15 mimetics.

Article Details

How to Cite
Okocha, C., Manafa, P., Anowi, J., Manafa, V., & Efobi, C. (2020). GDF -15 and Severity Scores in Sickle Cell Disease Patients Attending Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria. Journal of Advances in Medicine and Medical Research, 32(1), 31-37.
Original Research Article


Human Genomics in Global Health; 2019.
Available: (Assessed 27th April 2019)

Ademola Samson Adewoyin. Management of Sickle Cell Disease: A review for physician education in Nigeria (Sub-Saharan Africa), Anemia. 2015;21.
Article ID 791498.

Elguero E, Délicat-Loembet LM, Rougeron V, Arnathau C, Roche B, Becquart P, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci U S A. 2015;112(22):7051-4.
DOI: 10.1073/pnas.1505665112.
Epub 2015 May 4. PubMed
PMID: 25941403; PubMed Central PMCID: PMC4460506.

Okocha CE, Manafa PO, Ozomba JO, Ulasi TO, Chukwuma GO, Aneke JC. C-reactive protein and disease outcome in Nigerian sickle cell disease patients. Ann Med Health Sci Res. 2014;4:701-5.
DOI: 10.4103/2141-9248.141523.
PMID: 25328778, PMCID PMC4199159

Okocha EC, Manafa PO, Aneke JC, Onwuzuruike EC, Ibeh CN. Serum superoxide dismutase activity: A predictor of disease severity in Nigerian sickle cell anemia patients in steady state. Med J DY Patil University. 2017;10(5):406-411.

Manafa P, Okocha C, Nwogho B, et al. comparative study of carbohydrate antigen 19-9 in sickle cell disease subjects and controls in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. Afr Health Sci. 2018;18(4):1003–1009.
DOI: 10.4314/ahs.v18i4.21

Ago T, Sadoshima J. GDF15, a cardio-protective TGF‐β superfamily protein. Circ Res. 2006;98(3):294-7. PMID:16484622

Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, et al. Transforming growth factor-{beta} superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res. 2006;98(3): 351–360. PMID: 16397141

Robert P. Hebbel, Ischemia-reperfusion Injury in Sickle Cell Anemia: Relationship to Acute Chest Syndrome, Endothelial Dysfunction, Arterial Vasculopathy, and Inflammatory Pain. Hematol. Oncol. Clin. North. Am. 2014;28(2):181-98.
PMID: 24589261
DOI: 10.1016/j.hoc.2013.11.005

Odetunde IO, Chinawa JM, Achigbu KI, Achigbu EO. Body mass index and other anthropometric variables in children with sickle cell anaemia. Pak. J. Med. Sci. 2016:32(2):341–46.
DOI: 10.12669/pjms.322.9046
PMID: 27182236 PMCID: PMC4859019

PO Manafa, CE Okocha, JC Aneke, U Obiano, NC Ibeh, GO Chukwuma. Low serum glutathione-S-transferase activity and vitamin E levels do not correlate with disease severity in steady state adults with sickle cell anemia. J. Appl. Hematol. 2017: 8(3):110-15.
DOI: 10.4103/joah.joah_22_17

Carden DL, Granger DN. Pathophysiology of ischaemia–reperfusion injury. J. Pathol. 2000;190(3):255-66.
DOI:10.1002/(SICI)1096-9896(200002) 190:3<255::AID-PATH526>3.0.CO;2-6

Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Haematol. 2009; 84(9):618-25. PMID:19610078 PMCID: PMC3209715
DOI: 10.1002/ajh.21475

Headland SE, Norling LV. The resolution of inflammation: Principles and Challenges. Semin Immunol.2015;27(3):149–60. PMID: 25911383
DOI: 10.1016/j.smim.2015.03.014

Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, et al. The transforming growth factor-beta super-family member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res. 2006;98:351–60.
PMID: 16397141.

Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, et al. GDF 15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17(5): 581 8.
PMID: 21516086
DOI: 10.1038/nm.2354

Zhang M, Pan K, Liu Q, Zhou X, Jiang T, Li Y. Growth differentiation factor 15 may protect the myocardium from no-reflow by inhibiting the inflammatory-like response that predominantly involves neutrophil infiltration. Mol Med Rep. 2016;13(1):623–32. Available:

Tsumbu CN, Deby-Dupont G, Tits M, Angenot L, Franck T, Serteyn D, et al. Antioxidant and antiradical activities of Manihot esculenta Crantz (Euphorbiaceae) leaves and other selected tropical green vegetables investigated on lipoperoxidation and PMA activated monocytes. Nutrients. 2011;3(9):818–38.
PMID: 22254126 PMCID: PMC3257738
DOI: 10.3390/nu3090818

Tsumbu CN, Deby-Dupont G, Tits M, Angenot L, Frederich M, Kohnen S, et al. Polyphenol content and modulatory activities of some tropical dietary plant extracts on the oxidant activities of neutrophils and myeloperoxidase. Int J Mol Sci. 2012;13:628–50. DOI: 10.3390/ijms13010628 PMCID: PMC3269710 PMID: 22312276

Bahekar SE, Kale RS. Evaluation of antioxidant activity of Manihot esculenta Crantz in wistar rats. J Pharm Bioallied Sci 2016;8(2):119-23.
DOI: 10.4103/0975-7406.171697
PMID: 27134463 PMCID: PMC4832901

Larissi K, Politou M, Margeli A, Poziopoulos C, Flevari P, Terpos E. .The growth differentiation factor-15 levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia, correlate with hepcidin-25/Ferritin molar ratio and with markers of hemolysis, endothelial dysfunction and angiogenesis. Blood Cell Mol Dis. 2019; 77:137-41.
DOI: 10.1016/j.bcmd.2019.04.011
PMID: 31071550

Tantawy AA, Adly AA, Ismail EA, Darwish YW, Ali Zedan M. Growth differentiation factor-15 in young sickle cell disease patients: Relation to hemolysis, iron overload and vascular complications. Blood Cells Mol Dis. 2014;53(4):189–93. PMID: 25065856
DOI: 10.1016/j.bcmd.2014.07.003